← Human Trials & Peer-Reviewed Studies

The effect of combined functional training on BDNF, IGF-1, and their association with health-related fitness in the multiple sclerosis women

Plain-language guide to PMID 32305012 (2020): randomized controlled trial study of IGF-1 LR3, multiple sclerosis.

Key Facts

PMID
32305012
Journal
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
Year
2020
Study type
Randomized Controlled Trial
Authors
Abbaspoor E et al. (4 authors)
DOI
10.1016/j.ghir.2020.101320

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of IGF-1 LR3 in the context of multiple sclerosis, published as a randomized controlled trial.

Exercise-induced changes in the neurotrophic factors and the physical function are essential for the rehabilitation of the multiple sclerosis (MS) persons.

Who Took Part

By PubMed's age tags, the people studied were adults, women only.

Twenty women with relapsing-remitting MS randomly assigned to CFT and control (CON) groups.

How the Study Was Run

The researchers set it up as a randomized study.

The participants were allocated by chance, so the IGF-1 LR3 group and the comparison group should start out alike.

The CFT consisted of 8 weeks (3 days per week) rhythmic aerobic exercise, TRX suspension training, elastic band training, and bodyweight training.

BDNF, IGF-1, and health-related fitness components were assessed before and after the intervention.

What Was Measured

PubMed files the paper under topics including Brain-Derived Neurotrophic Factor, Case-Control Studies, Exercise, Insulin-Like Growth Factor I, Multiple Sclerosis, Relapsing-Remitting and Prognosis.

The authors tagged it with the keywords BDNF, Combined functional training, Fitness and IGF-1.

What This Means in Plain Language

The paper is a randomized study of IGF-1 LR3 in people with multiple sclerosis.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.

More context: the IGF-1 LR3 compound page, Multiple sclerosis research.

Our Notes on the Compound

IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.